{{Rsnum
|rsid=2297480
|Gene=FDPS
|Chromosome=1
|position=155309691
|Orientation=minus
|GMAF=0.4183
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
|Gene_s=FDPS,PKLR
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 51.3 | 38.1 | 10.6
| HCB | 4.4 | 40.4 | 55.1
| JPT | 7.1 | 38.4 | 54.5
| YRI | 49.7 | 47.6 | 2.7
| ASW | 38.6 | 47.4 | 14.0
| CHB | 4.4 | 40.4 | 55.1
| CHD | 10.3 | 43.9 | 45.8
| GIH | 53.5 | 40.6 | 5.9
| LWK | 48.2 | 42.7 | 9.1
| MEX | 41.4 | 46.6 | 12.1
| MKK | 51.3 | 43.6 | 5.1
| TSI | 60.4 | 34.7 | 5.0
| HapMapRevision=28
}}[[rs2297480]] is a SNP in the [[FDPS]] gene, which encodes an enzyme in the mevalonate pathway and therefore might alter the response to amino-bisphonate (drug) treatment of postmenopausal [[osteoporosis]].

A study of 234 Danish postmenopausal women treated for at least 2 years with amino-bisphonates concluded that [[rs2297480]](C;C) homozygotes do not respond as successfully as (A;A) or (A;C) genotypes.{{PMID|18687167}}

{{PharmGKB
|RSID=rs2297480
|Name_s=
|Gene_s=PKLR, FDPS
|Feature=
|Evidence=PubMed ID:18687167
|Annotation=This variant impacted the response to long-term N-bisphosphonates treatment in a study of 234 Danish postmenopausal women. Patients with the homozygous CC genotype showed a decreased response of bone turnover markers to amino-bisphosphonate therapy.
|Drugs=alendronate; ibandronate; pamidronate; risedronate; zoledronate
|Drug Classes=
|Diseases=Osteoporosis; Osteoporosis, Postmenopausal
|Curation Level=Curated
|PharmGKB Accession ID=PA164926327
}}

{{PMID Auto
|PMID=17368768
|Title=Farnesyl diphosphate synthase: a novel genotype association with bone mineral density in elderly women.
|OA=1
}}

{{PMID Auto
|PMID=19150398
|Title=Quantitative trait loci, genes, and polymorphisms that regulate bone mineral density in mouse.
|OA=1
}}

{{PMID Auto
|PMID=20191015
|Title=Genetic polymorphism of geranylgeranyl diphosphate synthase (GGSP1) predicts bone density response to bisphosphonate therapy in Korean women.
|OA=1
}}

{{PMID Auto
|PMID=21151198
|Title=Common allelic variants of the farnesyl diphosphate synthase gene influence the response of osteoporotic women to bisphosphonates.
}}

{{PMID Auto
|PMID=21196316
|Title=Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw.
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2297480
|overall_frequency_n=37
|overall_frequency_d=128
|overall_frequency=0.289062
|n_genomes=24
|n_genomes_annotated=0
|n_haplomes=30
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}